Diagrammatic description of the effect of anacetrapib monoclonal antibody on lipid profile and cardiovascular system Disclaimer: AAAS and EurekAlert! are not responsible for the accuracy of news ...

Merck & Co has said it will not file its cholesterol drug anacetrapib with regulators, saying that trial results are not good enough for clinical filings. The news came in a brief statement ...

No writing assistance was utilized in the production of this manuscript. Anacetrapib is an inhibitor of cholesteryl ester transfer protein that is in development to address residual cardiovascular ...

Remember CETP? It was a hot topic in cholesterol-lowering drug development a few years ago, but when Merck & Co finally pulled the plug on anacetrapib five years ago on lacklustre phase 3 data ...